(TRDA) Entrada Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 457m USD | Total Return: 39.6% in 12m

Stock Drug Delivery, RNA Therapeutics, Protein Therapeutics, Disease Treatment
Total Rating 48
Risk 79
Buy Signal 0.00
Biotechnology +0.2
Biotechnology +1.0
Market Cap: 457m
Avg Trading Vol: 2.53M USD
ATR: 6.79%
Peers RS (IBD): 69.8
Risk 5d forecast
Volatility61.6%
Rel. Tail Risk-3.40%
Reward TTM
Sharpe Ratio0.78
Alpha7.28
Character TTM
Beta1.449
Beta Downside1.164
Drawdowns 3y
Max DD76.75%
CAGR/Max DD-0.06
EPS (Earnings per Share) EPS (Earnings per Share) of TRDA over the last years for every Quarter: "2021-03": -7.0819, "2021-06": -0.45, "2021-09": -9.78, "2021-12": -0.89, "2022-03": -0.69, "2022-06": -0.74, "2022-09": -0.8, "2022-12": -0.79, "2023-03": -0.21, "2023-06": -0.78, "2023-09": 1.02, "2023-12": -0.29, "2024-03": 0.68, "2024-06": 1.5499, "2024-09": -0.35, "2024-12": 0.03, "2025-03": -0.42, "2025-06": -1.04, "2025-09": -1.06, "2025-12": -0.94,
EPS CAGR: -19.69%
EPS Trend: 0.4%
Last SUE: 0.35
Qual. Beats: 0
Revenue Revenue of TRDA over the last years for every Quarter: 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 25.26, 2023-06: 18.17, 2023-09: 43.735, 2023-12: 41.848, 2024-03: 59.12, 2024-06: 94.694, 2024-09: 19.57, 2024-12: 37.398, 2025-03: 20.558, 2025-06: 1.95, 2025-09: 1.614, 2025-12: 1.299,
Rev. CAGR: 14.99%
Rev. Trend: 30.8%
Last SUE: -0.24
Qual. Beats: 0
Risks
Technicals: volatile
Description: TRDA Entrada Therapeutics March 04, 2026

Entrada Therapeutics, Inc. (TRDA) is a clinical-stage biopharmaceutical company developing therapies for intracellular targets previously considered undruggable.

Their Endosomal Escape Vehicle (EEV) platform facilitates intracellular delivery of therapeutics, aiming for improved therapeutic index. This technology is applied to RNA and protein-based programs.

The company focuses on neuromuscular and ocular diseases, sectors within biotechnology that often involve complex genetic or protein-level interventions. Clinical-stage companies are typically pre-revenue and rely on successful drug development.

Incorporated in 2016 and headquartered in Boston, Massachusetts, TRDA was formerly known as CycloPorters, Inc. For more detailed financial and operational data, ValueRay offers comprehensive company profiles.

Headlines to Watch Out For
  • Clinical trial results for lead drug candidates
  • Regulatory approval of new genetic medicines
  • Competition from other gene therapies
  • Funding for research and development activities
  • Partnership agreements for drug commercialization
Piotroski VR‑10 (Strict, 0-10) 1.0
Net Income: -143.8m TTM > 0 and > 6% of Revenue
FCF/TA: -0.34 > 0.02 and ΔFCF/TA -25.83 > 1.0
NWC/Revenue: 1.11k% < 20% (prev 190.0%; Δ 918.5% < -1%)
CFO/TA -0.34 > 3% & CFO -128.5m > Net Income -143.8m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 12.53 > 1.5 & < 3
Outstanding Shares: last quarter (41.4m) vs 12m ago -3.90% < -2%
Gross Margin: -58.72% > 18% (prev 0.98%; Δ -5.97k% > 0.5%)
Asset Turnover: 5.63% > 50% (prev 40.05%; Δ -34.42% > 0%)
Interest Coverage Ratio: -18.07 > 6 (EBITDA TTM -150.8m / Interest Expense TTM -8.37m)
Altman Z'' -3.72
A: 0.75 (Total Current Assets 306.3m - Total Current Liabilities 24.5m) / Total Assets 377.4m
B: -0.72 (Retained Earnings -273.1m / Total Assets 377.4m)
C: -0.33 (EBIT TTM -151.2m / Avg Total Assets 451.8m)
D: -3.82 (Book Value of Equity -272.4m / Total Liabilities 71.2m)
Altman-Z'' Score: -3.72 = D
Beneish M
DSRI: none (Receivables none/3.68m, Revenue 25.4m/210.8m)
GMI: 1.00 (fallback, negative margins)
AQI: 1.11 (AQ_t 0.01 / AQ_t-1 0.01)
SGI: 0.12 (Revenue 25.4m / 210.8m)
TATA: -0.04 (NI -143.8m - CFO -128.5m) / TA 377.4m)
Beneish M-Score: cannot calculate (missing components)
What is the price of TRDA shares? As of April 01, 2026, the stock is trading at USD 12.62 with a total of 266,030 shares traded.
Over the past week, the price has changed by +10.03%, over one month by +8.05%, over three months by +22.76% and over the past year by +39.60%.
Is TRDA a buy, sell or hold? Entrada Therapeutics has received a consensus analysts rating of 4.50. Therefore, it is recommended to buy TRDA.
  • StrongBuy: 2
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the TRDA price?
ISSUER TARGET UP/DOWN
Wallstreet Target Price 20 58.5%
Analysts Target Price 20 58.5%
TRDA Fundamental Data Overview March 30, 2026
P/E Forward = 3333.3333
P/S = 17.9667
P/B = 1.4169
Revenue TTM = 25.4m USD
EBIT TTM = -151.2m USD
EBITDA TTM = -150.8m USD
Long Term Debt = 50.9m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 4.14m USD (from shortTermDebt, last quarter)
Debt = 50.9m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -39.5m USD (from netDebt column, last quarter)
Enterprise Value = 212.0m USD (456.7m + Debt 50.9m - CCE 295.7m)
Interest Coverage Ratio = -18.07 (Ebit TTM -151.2m / Interest Expense TTM -8.37m)
EV/FCF = -1.64x (Enterprise Value 212.0m / FCF TTM -129.6m)
FCF Yield = -61.12% (FCF TTM -129.6m / Enterprise Value 212.0m)
 FCF Margin = -509.6% (FCF TTM -129.6m / Revenue TTM 25.4m)
 Net Margin = -565.5% (Net Income TTM -143.8m / Revenue TTM 25.4m)
 Gross Margin = -58.72% ((Revenue TTM 25.4m - Cost of Revenue TTM 40.3m) / Revenue TTM)
Gross Margin QoQ = 31.79% (prev none%)
Tobins Q-Ratio = 0.56 (Enterprise Value 212.0m / Total Assets 377.4m)
Interest Expense / Debt = 8.73% (Interest Expense 4.45m / Debt 50.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -119.4m (EBIT -151.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.53 (Total Current Assets 306.3m / Total Current Liabilities 24.5m)
Debt / Equity = 0.17 (Debt 50.9m / totalStockholderEquity, last quarter 306.1m)
 Debt / EBITDA = 0.26 (negative EBITDA) (Net Debt -39.5m / EBITDA -150.8m)
 Debt / FCF = 0.30 (negative FCF - burning cash) (Net Debt -39.5m / FCF TTM -129.6m)
 Total Stockholder Equity = 360.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.81% (Net Income -143.8m / Total Assets 377.4m)
RoE = -39.83% (Net Income TTM -143.8m / Total Stockholder Equity 360.9m)
RoCE = -36.71% (EBIT -151.2m / Capital Employed (Equity 360.9m + L.T.Debt 50.9m))
 RoIC = -33.09% (negative operating profit) (NOPAT -119.4m / Invested Capital 360.9m)
 WACC = 10.66% (E(456.7m)/V(507.7m) * Re(11.08%) + D(50.9m)/V(507.7m) * Rd(8.73%) * (1-Tc(0.21)))
Discount Rate = 11.08% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 11.35%
 [DCF] Fair Price = unknown (Cash Flow -129.6m)
 EPS Correlation: 0.36 | EPS CAGR: -19.69% | SUE: 0.35 | # QB: 0
Revenue Correlation: 30.80 | Revenue CAGR: 14.99% | SUE: -0.24 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-1.07 | Chg7d=+0.040 | Chg30d=+0.052 | Revisions Net=+0 | Analysts=6
EPS current Year (2026-12-31): EPS=-3.79 | Chg7d=+0.230 | Chg30d=+0.310 | Revisions Net=+1 | Growth EPS=-9.3% | Growth Revenue=-2.0%
EPS next Year (2027-12-31): EPS=-3.50 | Chg7d=+0.288 | Chg30d=+0.648 | Revisions Net=+0 | Growth EPS=+7.6% | Growth Revenue=+20.6%
[Analyst] Revisions Ratio: +0.00 (2 Up / 2 Down within 30d for Next Quarter)
Additional Sources for TRDA Stock Fund Manager Positions: Dataroma · Stockcircle